Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Director | June 26, 2026 | June 29, 2026 |
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director · Chief Executive Officer | October 13, 2026 | October 15, 2026 |
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | Director | June 02, 2026 | June 03, 2026 |
| Repare Therapeutics Inc.RPTX · Entity 68433 | Director | June 17, 2024 | June 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date June 26, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2036-06-25 | Direct | 40,000 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
CRISPR Therapeutics AG
Report date October 13, 2026 · Filed October 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 259,736 |
Ending reported balance
After 2026-10-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-13 · Exercise / conversion · Acquired 8,333 · Balance 263,834 F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Row 2 · 2026-10-14 · Sale · Disposed 4,098 · Balance 259,736 F2: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-10-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-13 · Exercise / conversion · Disposed 8,333 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3: This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3: This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.
Oruka Therapeutics, Inc.
Report date June 02, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.23 · Expires 2036-06-01 | Direct | 9,136 |
Reported balance
After 2026-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 9,136 · Balance 9,136 F1: The option vests as to 1/12 of the underlying shares monthly from June 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/12 of the underlying shares monthly from June 2, 2026.
Repare Therapeutics Inc.
Report date June 17, 2024 · Filed June 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2034-06-16 | Direct | 27,200 |
Reported balance
After 2024-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-17 · Grant · Acquired 27,200 · Balance 27,200 F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Centessa Pharmaceuticals plc
Report date June 24, 2026 · Filed June 24, 2026
Section 16 reporting ended · disclosed 2026-06-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.84 · Expires 2031-02-19 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Disposition to issuer · Disposed 208,474 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.87 · Expires 2032-06-30 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-24 · Disposition to issuer · Disposed 48,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.35 · Expires 2033-06-22 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-24 · Disposition to issuer · Disposed 48,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.89 · Expires 2034-06-25 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-24 · Disposition to issuer · Disposed 48,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.43 · Expires 2035-06-20 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-24 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement").
F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time.
F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2025 Filed Mar 12, 2025 23:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 9,973 | $42.42 | $423,054.66 |
DisclosureSEC source: 0000950170-25-038216 · ownership.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,890 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 23:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 19,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-038216 · ownership.xml · derivative · entry 6 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,500 Underlying: Common Shares · 19,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2023 with respect to 77,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2023 with respect to 77,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 23:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 19,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-038216 · ownership.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| February 19, 2025 Filed Feb 19, 2025 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 6,928 | $52.80 | $365,798.40 |
DisclosureSEC source: 0000950170-25-023385 · ownership.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,973 F2 · acquired: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 18,360 | $55.21 | $1,013,563.80 |
DisclosureSEC source: 0000950170-25-025000 · ownership.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,613 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.02 to $55.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 13,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023385 · ownership.xml · derivative · entry 5 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,250 Underlying: Common Shares · 13,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on February 18, 2022 with respect to 53,000 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. F3 · derivative.expiration_date: This restricted stock unit award was granted on February 18, 2022 with respect to 53,000 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 11,640 | $55.05 | $640,782.00 |
DisclosureSEC source: 0000950170-25-023385 · ownership.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,901 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.2850, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 13,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023385 · ownership.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| December 24, 2024 Filed Dec 27, 2024 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,751 | $0.00 Strike: $16.21 | $0.00 |
DisclosureSEC source: 0000950170-24-140846 · ownership.xml · derivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 13,751 shares Expires 2027-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on May 3, 2017 with respect to 100,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning May 31, 2017. Read SEC document |
| December 24, 2024 Filed Dec 27, 2024 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 13,751 | $16.21 | $222,903.71 |
DisclosureSEC source: 0000950170-24-140846 · ownership.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 15,000 | $55.10 | $826,564.50 |
DisclosureSEC source: 0000950170-24-133373 · ownership.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,540 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 6,879 | $56.27 | $387,081.33 |
DisclosureSEC source: 0000950170-24-126521 · ownership.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,540 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.00 to $56.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 23,121 | $55.43 | $1,281,597.03 |
DisclosureSEC source: 0000950170-24-126521 · ownership.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,419 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-115694 · ownership.xml · derivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Shares · 400,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on October 16, 2024 with respect to 400,000 Common Shares, with (i) one quarter of the shares vesting on October 16, 2025, (ii) one quarter of the shares vesting on October 16, 2026, (iii) one quarter of the shares vesting on October 16, 2027, and (iv) one quarter of the shares vesting on October 16, 2028. F3 · derivative.expiration_date: This restricted stock unit award was granted on October 16, 2024 with respect to 400,000 Common Shares, with (i) one quarter of the shares vesting on October 16, 2025, (ii) one quarter of the shares vesting on October 16, 2026, (iii) one quarter of the shares vesting on October 16, 2027, and (iv) one quarter of the shares vesting on October 16, 2028. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $49.00 | $0.00 |
DisclosureSEC source: 0000950170-24-115694 · ownership.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Shares · 55,000 shares Expires 2034-10-16 F1 · derivative.exercise_date: This option was granted on October 16, 2024 with respect to 55,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 16, 2024. Read SEC document |
| October 14, 2024 Filed Oct 15, 2024 22:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 4,293 | $46.28 | $198,680.04 |
DisclosureSEC source: 0000950170-24-114786 · ownership.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,540 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| October 13, 2024 Filed Oct 15, 2024 22:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 8,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114786 · ownership.xml · derivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Shares · 8,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026. F3 · derivative.expiration_date: This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026. Read SEC document |
| October 13, 2024 Filed Oct 15, 2024 22:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 8,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114786 · ownership.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GiftCommon Shares | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-095615 · ownership.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,500 F1 · balance_after: Reflects 114,378 shares previously transferred from the Kulkarni 2023 GRAT to the Reporting Person. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 20:32 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | GrantShare Option (right to buy) · Derivative | 48,000 | $0.00 Strike: $8.89 | $0.00 |
DisclosureSEC source: 0001847903-24-000104 · wk-form4_1719520334.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Ordinary Shares · 48,000 shares Expires 2034-06-25 F1 · derivative.exercise_date: The shares subject to such option will vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of shareholders, subject to continued service as a director through the applicable vesting date. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:35 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantStock Option (right to buy) · Derivative | 27,200 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-24-017656 · form4-06202024_040608.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,200 Underlying: Common Shares · 27,200 shares Expires 2034-06-16 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| June 06, 2024 Filed Jun 6, 2024 21:55 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 30,550 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001415889-24-015828 · form4-06062024_090611.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,550 Underlying: Common Stock · 30,550 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 6, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,582 | $0.00 Strike: $19.12 | $0.00 |
DisclosureSEC source: 0000950170-24-045196 · ownership.xml · derivative · entry 5 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 19,582 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on December 1, 2017 with respect to 260,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning January 1, 2018. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,204 | $60.40 | $72,721.96 |
DisclosureSEC source: 0000950170-24-045196 · ownership.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,122 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.36 to $60.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 18,378 | $59.88 | $1,100,509.56 |
DisclosureSEC source: 0000950170-24-045196 · ownership.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,326 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.355 to $60.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 19,582 | $19.12 | $374,407.84 |
DisclosureSEC source: 0000950170-24-045196 · ownership.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 227,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 78,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-035515 · ownership.xml · derivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Shares · 78,750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 20, 2024 with respect to 78,750 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 20, 2024 with respect to 78,750 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $72.94 | $0.00 |
DisclosureSEC source: 0000950170-24-035515 · ownership.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Shares · 105,000 shares Expires 2034-03-20 F1 · derivative.exercise_date: This option was granted on March 20, 2024 with respect to 105,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2024. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $19.12 | $0.00 |
DisclosureSEC source: 0000950170-24-032989 · ownership.xml · derivative · entry 5 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,582 Underlying: Common Shares · 20,000 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on December 1, 2017 with respect to 260,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning January 1, 2018. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 9,387 | $73.06 | $685,817.97 |
DisclosureSEC source: 0000950170-24-032989 · ownership.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,122 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.47 to $73.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 10,613 | $71.97 | $763,810.18 |
DisclosureSEC source: 0000950170-24-032989 · ownership.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 217,509 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.47 to $72.445, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 20,000 | $19.12 | $382,400.00 |
DisclosureSEC source: 0000950170-24-032989 · ownership.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 228,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2024 Filed Mar 12, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 4,583 | $74.44 | $341,158.52 |
DisclosureSEC source: 0000950170-24-030189 · ownership.xml · nonDerivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,122 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 9,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-030189 · ownership.xml · derivative · entry 7 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F4 · derivative.exercise_date: This restricted stock unit award was granted on March 11, 2021 with respect to 36,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. F4 · derivative.expiration_date: This restricted stock unit award was granted on March 11, 2021 with respect to 36,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 9,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-030189 · ownership.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 9,802 | $78.26 | $767,104.52 |
DisclosureSEC source: 0000950170-24-030189 · ownership.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,705 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 19,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-030189 · ownership.xml · derivative · entry 6 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,750 Underlying: Common Shares · 19,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2023 with respect to 77,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2023 with respect to 77,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 19,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-030189 · ownership.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 6,370 | $79.67 | $507,497.90 |
DisclosureSEC source: 0000950170-24-018174 · ownership.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,257 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 13,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-018174 · ownership.xml · derivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,500 Underlying: Common Shares · 13,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on February 18, 2022 with respect to 53,000 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. F3 · derivative.expiration_date: This restricted stock unit award was granted on February 18, 2022 with respect to 53,000 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 13,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-018174 · ownership.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $19.12 | $0.00 |
DisclosureSEC source: 0000950170-24-016574 · ownership.xml · derivative · entry 6 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,582 Underlying: Common Shares · 20,000 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on December 1, 2017 with respect to 260,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning January 1, 2018. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,100 | $81.66 | $89,830.95 |
DisclosureSEC source: 0000950170-24-016574 · ownership.xml · nonDerivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,377 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2023 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.55 to $81.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 5,951 | $81.04 | $482,256.54 |
DisclosureSEC source: 0000950170-24-016574 · ownership.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,477 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2023 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.55 to $81.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 12,949 | $79.94 | $1,035,089.97 |
DisclosureSEC source: 0000950170-24-016574 · ownership.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,428 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2023 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.40 to $80.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 20,000 | $19.12 | $382,400.00 |
DisclosureSEC source: 0000950170-24-016574 · ownership.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $19.12 | Not disclosed |
DisclosureSEC source: 0000950170-24-009505 · ownership.xml · derivative · entry 5 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 50,000 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: This performance-based stock option was granted on December 1, 2017 with respect to 150,000 Common Shares and was subject to both time- and performance-based vesting. Performance-based stock options vested as to 112,500 options on December 1, 2020 and 37,500 options on December 1, 2021, based on the Company's performance over the applicable performance period, and subject to the terms and conditions of the agreement evidencing the award and the Company's 2016 Stock Option and Incentive Plan. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 700 | $61.10 | $42,769.86 |
DisclosureSEC source: 0000950170-24-009505 · ownership.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,377 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2023 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.04 to $61.155, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 49,300 | $60.50 | $2,982,802.83 |
DisclosureSEC source: 0000950170-24-009505 · ownership.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,077 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2023 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.04 to $61.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 50,000 | $19.12 | $956,000.00 |
DisclosureSEC source: 0000950170-24-009505 · ownership.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.